Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Stopped This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial.
Conditions
- Hematological Malignancies
Interventions
- DRUG: Magrolimab
- DRUG: Azacitidine
Sponsor
Gilead Sciences